Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]

This article refers to:

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study

Ichinose M, Nishimura M, Akimoto M, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:2147–2156.

On page 2152, Figure 3 should be presented as follows:

Figure 3 Annualized rate of COPD exacerbations by treatment group.

Notes: Error bars represent the 99% CI for rate of moderate-to-severe COPD exacerbations and the 95% CI for rate of severe COPD exacerbations. Listed values are RR (CI: *99% CI; ^95% CI), p-value. Negative binominal model, adjusted for treatment exposure. The duration of an event is not included in the calculation of a patient’s exposure.
Abbreviations: OLO, olodaterol; TIO, tiotropium; RR, rate ratio.